Skip to content
Phenprocoumon
Liquamar (phenprocoumon) is a small molecule pharmaceutical. Phenprocoumon was first approved as Liquamar on 1982-01-01. It is used to treat pulmonary embolism, thromboembolism, and venous thrombosis in the USA. The pharmaceutical is active against vitamin K epoxide reductase complex subunit 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phenprocoumon
Tradename
Company
Number
Date
Products
LIQUAMAROrganonN-011228 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pulmonary embolismEFO_0003827D011655I26
thromboembolismHP_0001907D013923—
venous thrombosisHP_0004936D020246I82.40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AA: Vitamin k antagonists
— B01AA04: Phenprocoumon
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PheochromocytomaD010673——12—3
ParagangliomaD010235——11—2
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiopulmonary bypassD002315—1——12
Congenital heart defectsD006330HP_0001627Q24.9—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePHENPROCOUMON
INNphenprocoumon
Description
Phenprocoumon is a hydroxycoumarin that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenylpropyl group. It has a role as an anticoagulant and an EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O
Identifiers
PDB—
CAS-ID435-97-2
RxCUI8150
ChEMBL IDCHEMBL1465
ChEBI ID50438
PubChem CID54680692
DrugBankDB00946
UNII IDQ08SIO485D (ChemIDplus, GSRS)
Target
Agency Approved
VKORC1
VKORC1
Organism
Homo sapiens
Gene name
VKORC1
Gene synonyms
VKOR
NCBI Gene ID
79001
Protein name
vitamin K epoxide reductase complex subunit 1
Protein synonyms
phylloquinone epoxide reductase, vitamin K dependent clotting factors deficiency 2, Vitamin K1 2,3-epoxide reductase subunit 1, vitamin K1 epoxide reductase (warfarin-sensitive)
Uniprot ID
Q9BQB6
Mouse ortholog
Vkorc1 (27973)
vitamin K epoxide reductase complex subunit 1 (Q9CRC0)
Alternate
No data
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000002211VKORC1, -1639G>Adrug response2021-11-191A
VCV000037344VKORC1, 174-136C>Tdrug response2021-03-291B
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,063 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
65 adverse events reported
View more details